PFM Health Sciences LP lessened its holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP – Free Report) by 4.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,000,787 shares of the biotechnology company’s stock after selling 519,444 shares during the period. PFM Health Sciences LP owned approximately 3.91% of Adaptimmune Therapeutics worth $9,505,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Fullcircle Wealth LLC bought a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $33,000. Vontobel Holding Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $95,000. FMR LLC raised its holdings in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after purchasing an additional 50,419 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Adaptimmune Therapeutics by 28.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after purchasing an additional 394,566 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Guggenheim lowered their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. HC Wainwright reduced their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $2.79.
Adaptimmune Therapeutics Stock Down 0.6 %
ADAP opened at $0.72 on Friday. The company has a fifty day moving average price of $0.81 and a 200-day moving average price of $1.00. The firm has a market capitalization of $184.41 million, a P/E ratio of -3.28 and a beta of 2.26. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics plc has a one year low of $0.43 and a one year high of $2.05.
Adaptimmune Therapeutics Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
- Five stocks we like better than Adaptimmune Therapeutics
- Where to Find Earnings Call Transcripts
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- What Are Dividend Achievers? An Introduction
- MarketBeat Week in Review – 11/25 – 11/29
- Energy and Oil Stocks Explained
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics plc (NASDAQ:ADAP – Free Report).
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.